|
1
|
Moran GW, Leslie FC, Levison SE,
Worthington J and McLaughlin JT: Enteroendocrine cells: neglected
players in gastrointestinal disorders? Therap Adv Gastroenterol.
1:51–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Salhy M, Seim I, Chopin L, Gundersen D,
Hatlebakk JG and Hausken T: Irritable bowel syndrome: the role of
gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Salhy M, Ostgaard H, Gundersen D,
Hatlebakk JG and Hausken T: The role of diet in the pathogenesis
and management of irritable bowel syndrome (Review). Int J Mol Med.
29:723–731. 2012.PubMed/NCBI
|
|
4
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Irritable bowel syndrome: diagnosis, pathogenesis and
treatment options. Nova Science Publishers Inc; New York: 2012
|
|
5
|
Sternini C, Anselmi L and Rozengurt E:
Enteroendocrine cells: a site of ‘taste’ in gastrointestinal
chemosensing. Curr Opin Endocrinol Diabetes Obes. 15:73–78.
2008.
|
|
6
|
Sternini C: Taste receptors in the
gastrointestinal tract. IV. Functional implications of bitter taste
receptors in gastrointestinal chemosensing. Am J Physiol
Gastrointest Liver Physiol. 292:G457–G461. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raybould HE: Gut chemosensing:
interactions between gut endocrine cells and visceral afferents.
Auton Neurosci. 153:41–46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raybould HE: Nutrient sensing in the
gastrointestinal tract: possible role for nutrient transporters. J
Physiol Biochem. 64:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bertrand PP and Bertrand RL: Serotonin
release and uptake in the gastrointestinal tract. Auton Neurosci.
153:47–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akiba Y and Kaunitz JD: Luminal
chemosensing in the duodenal mucosa. Acta Physiol (Oxf). 201:77–84.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steinert RE and Beglinger C: Nutrient
sensing in the gut: interactions between chemosensory cells,
visceral afferents and the secretion of satiation peptides. Physiol
Behav. 105:62–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakamura E, Hasumura M, Uneyama H and
Torii K: Luminal amino acid-sensing cells in gastric mucosa.
Digestion. 83(Suppl 1): 13–18. 2011. View Article : Google Scholar
|
|
13
|
Tolhurst G, Reimann F and Gribble FM:
Intestinal sensing of nutrients. Handb Exp Pharmacol. 309–335.
2012. View Article : Google Scholar
|
|
14
|
Mace OJ, Schindler M and Patel S: The
regulation of K- and L-cell activity by GLUT2 and the
calcium-sensing receptor CasR in rat small intestine. J Physiol.
590:2917–2936. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Salhy M, Lillebo E, Reinemo A and
Salmelid L: Ghrelin in patients with irritable bowel syndrome. Int
J Mol Med. 23:703–707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dizdar V, Spiller R, Singh G, et al:
Relative importance of abnormalities of CCK and 5-HT (serotonin) in
Giardia-induced post-infectious irritable bowel syndrome and
functional dyspepsia. Aliment Pharmacol Ther. 31:883–891.
2010.PubMed/NCBI
|
|
17
|
El-Salhy M, Vaali K, Dizdar V and Hausken
T: Abnormal small-intestinal endocrine cells in patients with
irritable bowel syndrome. Dig Dis Sci. 55:3508–3513. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El-Salhy M, Gundersen D, Ostgaard H,
Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of
serotonin and peptide YY cells in the colon of patients with
irritable bowel syndrome. Dig Dis Sci. 57:873–878. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Abnormal rectal endocrine cells in patients with
irritable bowel syndrome. Regul Pept. 188:60–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coates MD, Mahoney CR, Linden DR, et al:
Molecular defects in mucosal serotonin content and decreased
serotonin reuptake transporter in ulcerative colitis and irritable
bowel syndrome. Gastroenterology. 126:1657–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang SH, Dong L, Luo JY, et al: Decreased
expression of serotonin in the jejunum and increased numbers of
mast cells in the terminal ileum in patients with irritable bowel
syndrome. World J Gastroenterol. 13:6041–6047. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK
and Cho SW: The alteration of enterochromaffin cell, mast cell, and
lamina propria T lymphocyte numbers in irritable bowel syndrome and
its relationship with psychological factors. J Gastroenterol
Hepatol. 23:1689–1694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JH, Rhee PL, Kim G, et al:
Enteroendocrine cell counts correlate with visceral
hypersensitivity in patients with diarrhoea-predominant irritable
bowel syndrome. Neurogastroenterol Motil. 18:539–546. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim HS, Lim JH, Park H and Lee SI:
Increased immunoendocrine cells in intestinal mucosa of
postinfectious irritable bowel syndrome patients 3 years after
acute Shigella infection: an observation in a small case
control study. Yonsei Med J. 51:45–51. 2010.PubMed/NCBI
|
|
25
|
Dunlop SP, Coleman NS, Blackshaw E, et al:
Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel
syndrome. Clin Gastroenterol Hepatol. 3:349–357. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spiller RC, Jenkins D, Thornley JP, et al:
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and
increased gut permeability following acute Campylobacter
enteritis and in post-dysenteric irritable bowel syndrome. Gut.
47:804–811. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
El-Salhy M, Lomholt-Beck B and Hausken T:
Chromogranin A as a possible tool in the diagnosis of irritable
bowel syndrome. Scand J Gastroenterol. 45:1435–1439. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
El-Salhy M, Mazzawi T, Gundersen D and
Hausken T: Chromogranin A cell density in the rectum of patients
with irritable bowel syndrome. Mol Med Rep. 6:1223–1225.
2012.PubMed/NCBI
|
|
29
|
Longstreth GF, Thompson WG, Chey WD,
Houghton LA, Mearin F and Spiller RC: Functional bowel disorders.
Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Spiller R, Aziz Q, Creed F, et al:
Guidelines on the irritable bowel syndrome: mechanisms and
practical management. Gut. 56:1770–1798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roalfe AK, Roberts LM and Wilson S:
Evaluation of the Birmingham IBS symptom questionnaire. BMC
Gastroenterol. 8:302008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Talley NJ, Verlinden M and Jones M:
Quality of life in functional dyspepsia: responsiveness of the
Nepean Dyspepsia Index and development of a new 10-item short form.
Aliment Pharmacol Ther. 15:207–216. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arslan G, Lind R, Olafsson S, Florvaag E
and Berstad A: Quality of life in patients with subjective food
hypersensitivity: applicability of the 10-item short form of the
Nepean Dyspepsia Index. Dig Dis Sci. 49:680–687. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Patrick DL, Drossman DA, Frederick IO,
DiCesare J and Puder KL: Quality of life in persons with irritable
bowel syndrome: development and validation of a new measure. Dig
Dis Sci. 43:400–411. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Drossman DA, Patrick DL, Whitehead WE, et
al: Further validation of the IBS-QOL: a disease-specific
quality-of-life questionnaire. Am J Gastroenterol. 95:999–1007.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gershon MD and Tack J: The serotonin
signaling system: from basic understanding to drug development for
functional GI disorders. Gastroenterology. 132:397–414. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gershon MD: Plasticity in serotonin
control mechanisms in the gut. Curr Opin Pharmacol. 3:600–607.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gershon MD: 5-Hydroxytryptamine
(serotonin) in the gastrointestinal tract. Curr Opin Endocrinol
Diabetes Obes. 20:14–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gershon MD: Serotonin is a sword and a
shield of the bowel: serotonin plays offense and defense. Trans Am
Clin Climatol Assoc. 123:268–280. 2012.PubMed/NCBI
|
|
40
|
Camilleri M, Andrews CN, Bharucha AE, et
al: Alterations in expression of p11 and SERT in mucosal biopsy
specimens of patients with irritable bowel syndrome.
Gastroenterology. 132:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Camilleri M, Busciglio I, Carlson P, et
al: Candidate genes and sensory functions in health and irritable
bowel syndrome. Am J Physiol Gastrointest Liver Physiol.
295:G219–G225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kumar S, Ranjan P, Mittal B and Ghoshal
UC: Serotonin transporter gene (SLC6A4) polymorphism in patients
with irritable bowel syndrome and healthy controls. J
Gastrointestin Liver Dis. 21:31–38. 2012.PubMed/NCBI
|
|
43
|
Park JM, Choi MG, Park JA, et al:
Serotonin transporter gene polymorphism and irritable bowel
syndrome. Neurogastroenterol Motil. 18:995–1000. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Saito YA, Locke GR III, Zimmerman JM, et
al: A genetic association study of 5-HTT LPR and GNbeta3 C825T
polymorphisms with irritable bowel syndrome. Neurogastroenterol
Motil. 19:465–470. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wendelbo I, Mazzawi T and El-Salhy M:
Increased serotonin transporter immunoreactivity intensity in the
ileum of patients with irritable bowel disease. Mol Med Rep.
9:180–184. 2013.PubMed/NCBI
|
|
46
|
El-Salhy M, Wendelbo I and Gundersen D:
Serotonin and serotonin transporter in the rectum of patients with
irritable bowel disease. Mol Med Rep. 8:451–455. 2013.PubMed/NCBI
|
|
47
|
Schubert ML: Gastric secretion. Curr Opin
Gastroenterol. 27:536–542. 2011. View Article : Google Scholar
|
|
48
|
Schubert ML: Gastric secretion. Curr Opin
Gastroenterol. 26:598–603. 2010. View Article : Google Scholar
|
|
49
|
Schubert ML: Gastric secretion. Curr Opin
Gastroenterol. 23:595–601. 2007. View Article : Google Scholar
|
|
50
|
Schubert ML: Gastric secretion. Curr Opin
Gastroenterol. 18:639–649. 2002. View Article : Google Scholar
|
|
51
|
Chu S and Schubert ML: Gastric secretion.
Curr Opin Gastroenterol. 28:587–593. 2012. View Article : Google Scholar
|
|
52
|
Van Citters GW and Lin HC: Ileal brake:
neuropeptidergic control of intestinal transit. Curr Gastroenterol
Rep. 8:367–373. 2006.PubMed/NCBI
|
|
53
|
Pourhoseingholi A, Vahedi M,
Pourhoseingholi MA, et al: Irritable bowel syndrome,
gastro-oesophageal reflux disease and dyspepsia: overlap analysis
using loglinear models. Arab J Gastroenterol. 13:20–23. 2012.
View Article : Google Scholar
|
|
54
|
Kim HG, Lee KJ, Lim SG, Jung JY and Cho
SW: G-protein beta3 subunit C825T polymorphism in patients with
overlap syndrome of functional dyspepsia and irritable Bowel
syndrome. J Neurogastroenterol Motil. 18:205–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Suzuki H and Hibi T: Overlap syndrome of
functional dyspepsia and irritable bowel syndrome - are both
diseases mutually exclusive? J Neurogastroenterol Motil.
17:360–365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nakajima S, Takahashi K, Sato J, et al:
Spectra of functional gastrointestinal disorders diagnosed by Rome
III integrative questionnaire in a Japanese outpatient office and
the impact of overlapping. J Gastroenterol Hepatol. 25(Suppl 1):
S138–S143. 2010. View Article : Google Scholar
|
|
57
|
Olafsdottir LB, Gudjonsson H, Jonsdottir
HH and Thjodleifsson B: Stability of the irritable bowel syndrome
and subgroups as measured by three diagnostic criteria - a 10-year
follow-up study. Aliment Pharmacol Ther. 32:670–680.
2010.PubMed/NCBI
|
|
58
|
Kaji M, Fujiwara Y, Shiba M, et al:
Prevalence of overlaps between GERD, FD and IBS and impact on
health-related quality of life. J Gastroenterol Hepatol.
25:1151–1156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Noh YW, Jung HK, Kim SE and Jung SA:
Overlap of erosive and non-erosive reflux diseases with functional
gastrointestinal disorders according to rome III criteria. J
Neurogastroenterol Motil. 16:148–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hori K, Matsumoto T and Miwa H: Analysis
of the gastrointestinal symptoms of uninvestigated dyspepsia and
irritable bowel syndrome. Gut Liver. 3:192–196. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ford AC, Marwaha A, Lim A and Moayyedi P:
Systematic review and meta-analysis of the prevalence of irritable
bowel syndrome in individuals with dyspepsia. Clin Gastroenterol
Hepatol. 8:401–409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang LH, Fang XC and Pan GZ: Bacillary
dysentery as a causative factor of irritable bowel syndrome and its
pathogenesis. Gut. 53:1096–1101. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dunlop SP, Jenkins D, Neal KR and Spiller
RC: Relative importance of enterochromaffin cell hyperplasia,
anxiety, and depression in postinfectious IBS. Gastroenterology.
125:1651–1659. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
El-Salhy M, Gundersen D, Gilja OH,
Hatlebakk JG and Hausken T: Is irritable bowel syndrome an organic
disorder? World J Gastroenterol. 2:384–400. 2014. View Article : Google Scholar
|
|
65
|
El-Salhy M, Hatlebakk JG, Gilja OH and
Hausken T: Irritable bowel syndrome: recent developments in
diagnosis, pathophysiology, and treatment. Expert Rev Gastroenterol
Hepatol. 8:435–443. 2014. View Article : Google Scholar : PubMed/NCBI
|
